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Aims
The purpose of this paper is to use a case
study to illustrate an encounter with aggressive
wet Age-related Macular Degeneration (wet
AMD) and discuss clinical interpretation issues
related to primary care optometry.
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lntroduction
Age-related Macular Degeneration (AMD) is
a major cause of visual impairment in Australia
and the devetoped wortd (AIHW, 2005). Robyn
Guymer describes how in AMD .Vision is lost
either from a slow atrophic process (dry AMD)
or from a much more rapid and destructive
process of choroidal neovascularisation (wet
AMD)" (2007. p 276).
Following a recent scientific breakthrough,
wet AMD can now be treated with anti-VEbF
tlrugs lhat can halt the growth of new blood
vcssels and retain central eye sight (Fong et
;rl , 2(X)ll, tl;rtorr, 2009). Originally developed
,r,, ,r rrovr:l (:iut(;(!r lreatrnent to block the action
ul V.r:,r.rrl.rr I rrrlollrchirl Growth Factor (VEGF);
llrr..,r.,rrrlr .ilt(lto(flrn()tils tllttqs were found tO
limit the production of new blood vessels in
fast growing tumours and coincidentally halt the
choroidal neovascularisation process in
wet AMD.
Angiogenesis is a term used to describe
the growth of new blood vessels, and goes
back to the work of surgeon John Hunter in
1787 (Hess, 2006). Angiogenesis was identified
by Judah Folkman (1971) as a potential method
of fighting cancer by attacking its blood supply.
Following Folkman's work, a broader study on
growth factor at Genentech identified VEGF
factors identicalto the tumorVEGF factors
discovered earlier (Leung et al., 1ggg, Folkman
et al., 1971).
This led to the exciting development of
bevacizumab or Avastin, a mouse derived
full-length humanized anti-VEGF monoctonat
antibody, and was to be used to treat metast;rtrr.
colorectal cancer (Hurwitz and Kabbinavar
2005). Later bevacizumab (Avasitin) was use<t
for other applications and Michaels et at.(2005)
and Rosenfeld et al.(2005) trialled it on patierrtr;
in the hope of controlling wet AMD firsily wrilr
systemic application and then intravitreal
injections (as cited by Krebs et at., 2009)
Eventually four long term trials of the rr:l;rtr:rt
drug ranibizumab or Lucentis were condur;lcrl
and published.
" Lu centis@ (ran ib izu m ab, formerly Rh u F ab
V2) is a modified fragment of an anti-VEGF
antibody (Avastin@) that binds and inhibits all
VEGF isoforms (Krzystolik et al., 2002). lnitial
sfudles with the full length antibody suggesfed
that it did not penetrate the retina when injected
into the vitreous cavity (Mordenti, 1999).
However, the Fab fragment passed easily
through the retina to reach the target (subretinal)
space. An affinity maturation process was
applied to increase the binding affinity to VEGF
14}-fold, and Lucentis@ was moved into clinical
studles. The results from four large randomized
clinicaltrials have been reported to date. (CATT,
2008: p 1.5)"
The CATT Study Group are currently
investigating Lucentis and Avastin in head-
to-head trials and they have noted that initial
reports of poor retinal penetration of the full
length antibody were challenged by later
studies (CATT, 2008: p 1.7): "ln addition, when
Avastin@ was injected into the vitreous of
rabbits, it showed full penetration of the retina
(Shahar, 2006; Feiner, 2006; Schraemeyer,
ARVO 2006).' ln any case the drug Lucentis@
received approval (US BL 125156) fortreatment
'of neovascular AMD on June 30, 2006, but
Avastin requires further research, clinical trials
and licensing application by Genentech to
receive FDA approval (Raftery et al., 2007).
It is commonly known that wet AMD has a
large impact on an individual's quality of life
and it comes at a large cost to our ailing health
system. Many studies simply use economic
and epidemiological data to argue the relative
benefits of funding research, and the resultant
subsidy of new treatment and diagnostic
methods for wet AMD. However, when looking
at someone's health, it must not be seen as
purely a numbers game. Studies that focus on
using preventative techniques to reduce the
social impact of AMD, and research in low vision
and rehabilitation of visual function in those
people affected by AMD also have an equally
important role to play in developing a modern
approach to this disabling condition (for a global
perspective on Low Vision see: Herse, 2008).
Case Report of Aggressive Age-related
Macular Degeneration
Mr SL is now in his eighties and is stillquite
active; he enjoys travelling and also researching
local coal mining history. He reports: "This
involves field visits, interviewing older people,
research at Wollongong Library and the
University, reading many books and writing. lt is
imperative that I retain at least partial eyesight
to continue with this work." He also suffers from
chronic kidney disease and is on dialysis and
exchange bags four times daily: "This condition
has put a stop to major activities such as flying
and travelling long distances by bus or train.
Holidays are therefore curtailed." Finally, he
has severe arthritis in both knees which makes
walking difficult: "Life would be made far more
difficult if I could no longer drive."
Part One:
lnitial Presentation of Macular Disease
ln July 2005 Mr SL presented for routine eye
examination. He has been a long time client of
this practice.
He had slight cortical cataracts, pre-macular
fibrosis in the right eye, and slight macular
pigment changes in the lefi eye.
BCVA: R 6/7 L 617
ln August 2005 a review with a local
ophthalmologist confi rmed these fi ndings.
ln September 2005, SL returned because
vision in the right eye felt dim, and a slight
Amsler grid defect was noted but VA's and
fundus appeared unchanged. He was asked to
monitor central vision with an Amlser grid and
return if he noted problems.
ln November 2005, only 2 months later the
right eye changed dramatically.
BCVA: R 6/90 L 6t7
(a round grey blob was reported in the centre
of vision of the RE with no distortion on the
Amsler grid)
Prompt referral to retinal specialist confirmed
a right subfoveal choroidal neovascular
membrane. At this time classic subfoveal new
vessels were treated with Visudyne; with an aim
to reduce the amount of vision lost but with little
hope of regaining any functional visual acuity in
the eye (see: Treatment of Age-related Macular
.'t t
27
Degeneration With Photodynamic Therapy
(TAP) Study Group,2001). Later in Mr SL's
treatment the anti-VEGF drug Avastin became
available, in April 2006. Treatment with Avastin
intravitreal injections reduced the amount of
macular edema and the size of the subfoveal
vascular network. Despite this, there was no
improvement with vision from either treatment;
Mr SL's right eye developed a macular scar
resulting in a centralscotoma or blind spot (see
figure 1.1).
Part Two: Establishing Long Term approach
for Monitoring for Macular Disease
ln monitoring Mr SL, of major concern was
the length of time he had waited before returning
for a recheck of the right eye despite the huge
drop in VA. A misinterpretation of the disease
process could well have affected his long term
prognosis.
As his vision worsened Mr SL thought it
was an expected progression of the previously
diagnosed pre-macular change. He also lacked
an understanding on how to use the Amsler
chart and the importance of the test. lnstead of
looking at the amount of distortion, intensity of
blur, or more importantly the area affected by
the blur he was just looking out for 'distortions'
not aware lines could go completely missing.
Subsequently, emphasis was placed on
correct instructions, so that he could at least
monitor his relatively healthy left eye. ln part this
was easier now as Mr SL only had the central
vision in the left eye remaining and so even a
slight change in centralvision was bound to be
more noticeable.
Besides some slight nuclear sclerosis cataract
changes there was no major pathological issues
in the left eye threatening eye sight. Despite
this because of underlying pigment changes,
even without the presence of drusen, it was
considered quite possible that the left eye would
also become affected by aggressive Macular
disease at some point.
The dynamic of clinical referral for wet AMD
had changed dramatically over this period of
time with the introduction of OCT imaging and
potential of patients receiving anti-VEGF drug
therapy. This was some what of a motivating
factor as it was clear that Avastin had a clinical
effect of reducing the activity of the subfoveal
new vessel with Mr SL's right eye. lf a new
vessel was found growing in the left eye it was
hoped that Mr SL's central vision could be
saved by using the drug to stop the blood vessel
growing.
Over several subsequent visits to the
optometrist and ophthalmologist Mr SL's best
correct VA in the left eye deteriorated to 6/9
mainly due to advancing cataract. Then in June
2007 Mr SL made an appointment with the
optometrist after "observing line distortion on
the Amsler Chart." Best correction in the left
eye was now 6/18 but unstable and patchy. The
macular view was poor even with dilation due
to cataract changes obscuring the view, despite
this a small haemorrhage and minimalmacular
edema was detected (see also figure 1.1 and
1.2 taken later after resolution of most of the
new vessel signs).
Urgent referralto a retinalspecialist in
Sydney was arranged; being a Friday before
the June long weekend, Mr SL was seen by the
specialist that afternoon. The retinal specialist
confirmed Mr SL had neovascular changes in
the left eye. He more specifically diagnosed Mr
SL's eye disease as an aggressive variant of
Age-related Macular Degeneration called retinal
angiomatous proliferation or RAp (yannuzzi et
al.,2001).
Part Three: Long term Medical retinal
treatment and monitoring of vision
As previously discussed since the last time
Mr SL had a CNV (in the right eye) two major
technological advances in diagnosis and
treatment had become more readily available;
the Optical Coherence Tomography scanning
(OCT) and anti-VEGF therapy. After fluorescein
and OCT examination the retinal specialist
confirmed the RAP variant of AMD (retinal
angiomatous proliferation), and, on that same
Friday afternoon an intra-vitreal injection of
Avastin was given (Meyerle et al., 2007). This
time the new blood vesselwas found in time
for the drug to be effective in restoring clarity
to central vision. The central vision of the left
eye recovered to 6/12 with slight distortion
to the lower left of centre on the Amsler grid.
Monthly injections of Lucentis have been used
to stabilize the AMD since it became available
under PBS.
Mr SL continues his research in local history
and takes turns driving when he and his wife
travel;they have recently been down to Eden,
about 1000km away, in the car on a road trip.
The burden of ongoing treatment is something
that has changed Mr SL's life even though the
treatment effectively maintains his remaining
central vision. Thankfully local eye specialists
have begun to provide medical retinal
treatments and advanced retinal diagnosis and
imaging. Mr SL attends their rooms to have
regular injections of Lucentis and to check for
the stability of the macular in order to retain the
central vision of his left eye. Figure 1.1(below):
Retinal photo of Mr SL's right eye (photo
courtesy OPSM Wollongong).
Figure 1.2(below): Retinal photo Mr SL's left
eye (photo courtesy OPSM Wollongong). Two
months after beginning Anti-VEGF drug therapy
the macular area had stabilised.
Discussion
Timely referral is essentialfor CNV, especially
for this aggressive variant. lt is hoped that this
case study will increase awareness amongst
optometrists and the people they encounter
in their primary care role. Patients and eye
care professionals need to be aware that
with or without anti-VEGF therapy, whether
Avastin or Lucentis, early detection and timely
management of AMD is essential. This involves
clearly communicating with patients the disease
process to help to guard against poor outcomes
due to a lack of understanding of the signs or
symptoms of the disease.
Patients, Optometrists, Ophthalmologists
and the broader health system are on the front
line together against this blinding disease. We
all have an important role to play in patient
management, but whenever dealing with the
disease, we should not forget that we are also
dealing with the quality of a person's life.
Medical retinal diagnosis and treatment has
become more effective over the last five years
but AMD is such a huge problem for people in
the community. lt has long been recognised
that some research priorities gain precedence
over others for political and economic rather
than clinically derived reasons (Richards, 1991).
More specifically David Hess describes science
that is left incomplete or under-resourced for
political and economic reasons as "the problem
of undone science". According to Hess this
undone science can be the result of a systemic
effort by elites who put structures in place
that keeps research from being done (2007: p
23). As Guymer points out in the March 2007
Medical Journal of Australia (just 3 months
before Mr SL's left eye was affected by AMD):
' No p rospective rand omised sfudles
comparing ranibizumab (Lucentis) and
bevacizumab (Avastin) have taken place,
although there are plans for such a trial through
fhe US National Eye lnstitute. Untilfhe resu/fs
of such a comparative trial are fofthcoming,
government and the community face a dilemma
of whether to approve and subsldise the well
studied but expensive drug ranibizumab or
delay that decision and therefore condone the
off-label use of a drug (Avastin) that has not
been submitted to the rigours of a randomised
clinical trial nor sfudies to the extent that
we expect before a new drug is introduced.
(Guymer,2007)"
Mr SL's clinical experience has highlighted
the importance of addressing current issues
related to undone science of medical retina
research into angiogenesis occurring in AMD
and other ocular disease (for example CNV
secondary to Ocular Toxoplasmosis: Chan,
2008). The major undone science issue of the
yet to be completed Avastin-Lucentis head to
head trial (which is due to be completed in 201 1)
captures the key elements of the challenges
-
I
involved in reconstructing and reforming medical
science. Mr SL's plight in obtaining emergency
and ongoing treatment for his aggressive wet
AMD is intimately related to the controversy
surrounding this area (Brown et al., 2009,
Rosenfeld et al., 2006).
It is important to take time to remember that
the principal endeavour of primary care and all
health care is to take the meaning surrounding
health and illness and introduce it thoughtfully
within the space of the everyday.
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